Navigation Links
BD Board Declares Dividend
Date:7/24/2012

FRANKLIN LAKES, N.J., July 24, 2012 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 45 cents per common share, payable on September 28, 2012 to holders of record on September 7, 2012. The indicated annual dividend rate is $1.80 per share.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contacts:
Colleen T. White, Corporate Communications – 201-847-5369;
colleen_white@bd.com

Monique N. Dolecki, Investor Relations – 201-847-5378;
monique_dolecki@bd.com


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
2. Angeion Selects Hendrik Struik for Board of Directors
3. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
4. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
5. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
6. Young Innovations, Inc. Board Of Directors Declares Quarterly Dividend
7. Allscripts Adds Two Independent Directors to Board
8. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
9. Accuray Appoints Richard Pettingill, LFACHE to Board of Directors
10. Generex Augments Antigen Express Scientific Advisory Board
11. Israel Makov Appointed Chairman of Sun Pharma Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)... Aug. 21, 2014   Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced positive results from a ... histolyticum (or CCH) for the treatment of edematous ... the Phase 2a trial, all three doses of ... showed an improvement in the appearance of cellulite ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... ZURICH, July 16 An innovative ... fibrosis patients has received a second,orphan drug designation ... designation was,granted. The recent designation relates to Burkholderia ... fibrosis patients. For Axentis,Pharma AG of Zurich, Switzerland, ...
... , , , ... are a source of worry for many who fear Alzheimer,s ... July 16 issue of the New England Journal of Medicine suggests that ... to have memory declines in their mid-50s, far earlier than previously thought. ...
Cached Medicine Technology:Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 2Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 2Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 4Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 5Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 6Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 7
(Date:8/21/2014)... College of Chest Physicians (CHEST) announces the immediate ... Injured During Pandemics and Disasters: CHEST Consensus Statement ... journal CHEST while the global health-care ... The consensus statement aims to guide ethical decision-making, ... crises. The statement was developed by over 100 ...
(Date:8/21/2014)... (Aug. 21, 2014) An international scientific collaboration led ... genetic alterations that may contribute to a rare form ... this rare cancer but other types as well. , ... Health,s Cancer Genome Atlas initiative , completed the ... results today in the journal Cancer Cell . ...
(Date:8/21/2014)... Utah scientists have developed a genetically engineered line of ... new research on epilepsy, Alzheimer,s and other diseases. ... in degree of fluorescence in response to different calcium ... called astrocytes and microglia, to be studied in a ... to decipher how the brain works," said Petr ...
(Date:8/21/2014)... The Mount Sinai Hospital has expanded its ... captures real-time patient feedback and enables staff to make ... now available to admitted patients in the Hospital’s cardiology, ... satisfaction using smartphones. , "We are expanding our ... the timely information we need to respond to patient ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Greater awareness ... to have babies before they are full term has ... some areas of the country, early elective deliveries (EEDs) ... last 20 years, EED is defined as delivery before ... linked to neonatal morbidity and mortality, and offers no ...
Breaking Medicine News(10 mins):Health News:CHEST releases new expert guidance in care of the critically ill and injured 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 3Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 3Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 3
... window of vulnerability for developing binge eating disorder, especially ... study from the University of North Carolina at Chapel ... long-term study of 100,000 pregnant Norwegian women, the researchers ... eating disorder that began during pregnancy. The research is ...
... By furthering scientists understanding of the molecular mechanisms that ... majority of ineffective antibodies, the work may have implications ... The study was published on September 6, 2007, in ... of the effort to understand how protection against HIV ...
... to Peter B. Ajluni, D.O., American Osteopathic,Association (AOA) President, ... of,Americans without health insurance to 47 million --- as ... --- is a disturbing trend signaling,more must be done ... As lawmakers return this week from the summer recess, ...
... Sept. 6 H.E.A.R.T 911 is a,non-profit, non-sectarian ... fighters and construction trade union workers, all of,whom ... 11th attacks and,surviving family members of those who ... nation-wide to situations that arise during,natural or man-made ...
... promotes free quit-smoking services from ClearWay ... ... a,dramatic new billboard will catch the eye of motorists on Interstate ... a,giant ashtray, the billboard will call attention to QUITPLAN(R) Services,Clearway Minnesota,s ...
... Interactive Workshop Features CML Expert, Jorge Cortes, M.D., ... an,expert on leukemia, will discuss novel treatment approaches for ... CML: A,Model in Cancer Therapy. The program is scheduled ... ET. The program is being offered by The ...
Cached Medicine News:Health News:Pregnancy may increase the risk of developing binge eating disorder 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 3Health News:Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911. 2Health News:Award-winning QUITPLAN(R) Services Billboard Debuts in Rogers 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 3
... It takes powerful technology ... worker safety, and still lower ... SYNCHRON LX20 PRO, offering features ... on any other chemistry analyzer, ...
When it comes to providing speed, accuracy and menu flexibility, the SYNCHRON CX5 PRO has it all. The state-of-the-art CX5 PRO starts with the wide SYNCHRON chemistry menu to create the ideal full-se...
... user-friendly instrument is the ... analyzer for the medium ... a well established nephelometric ... for a wide range ...
Help restore pelvic muscle function with the Prometheus Pathway CTS 2000 evaluation and training system....
Medicine Products: